Accordingly, pursuant to the above Stipulation, and upon the consent and request of Plaintiffs and Deva, IT IS HEREBY ORDERED, ADJUDGED, AND DECREED THAT: Case 1:25-cv-01332-MN Document 36 Filed 06/15/26 Page 2 of 4 PageID #: 289 3 1. The filing of ANDA 219532 was a technical act of infringement of each of the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent under 35 U.S.C. § 271(e)(2)(A). 2. All other claims and defenses asserted by the parties against each other in Plaintiffs’ and Deva’s pleadings in the Action, including the allegations and averments contained therein, are hereby dismissed, without prejudice. 3. Deva, its officers, agents, servants, employees, and attorneys, and all other persons in active concert or participation with any of them who receive actual notice of this Order by personal service or otherwise, are hereby enjoined from manufacturing, using, offering to sell, or selling within the United States, or importing into the United States, the generic cariprazine hydrochloride capsule products (1.5 mg, 3 mg, 4.5 mg, and 6 mg) described by ANDA 219532 during the life of the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent, including any extensions and pediatric exclusivities thereof, absent a license agreement or other authorization by Plaintiffs, unless all of the claims of the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent are found invalid or unenforceable by a court decision from which no appeal has been or can be taken, other than a petition for a writ of certiorari to the U.S. Supreme Court. 4. Plaintiffs and Deva each expressly waive any right to appeal or otherwise move for relief from this Stipulation and Order. 5. This Court retains jurisdiction over Plaintiffs and Deva for purposes of enforcing this Stipulation and Order. 6. This Stipulation and Order shall finally resolve the Action.This Stipulation and Order is without prejudice to any claim, defense, or counterclaim in any possible future action between Deva and any of the Plaintiffs regarding the ’142 Patent, the ’621 Patent, the RE’350 Patent, the RE’110 Patent, and the RE’302 Patent and a product other than a generic cariprazine hydrochloride capsule product (1.5 mg, 3 mg, 4.5 mg, and 6 mg) described by ANDA 219532. "